{"id":380700,"date":"2020-11-13T07:21:24","date_gmt":"2020-11-13T12:21:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380700"},"modified":"2020-11-13T07:21:24","modified_gmt":"2020-11-13T12:21:24","slug":"swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/","title":{"rendered":"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)"},"content":{"rendered":"

<\/p>\n

Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) <\/b><\/p>\n

Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22<\/i><\/p>\n

Rolling review accepted based on preclinical, CMC, and clinical data available to date<\/i><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Moderna, Inc.<\/a>, (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Swissmedic has started a rolling review of mRNA-1273, the Company\u2019s vaccine candidate against COVID-19. This announcement follows positive results<\/a> from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults<\/a> (ages 18-55 years) and older adults<\/a> (ages 56-70 and 71+) published in the New England Journal of Medicine<\/i>.\n<\/p>\n

\nModerna has initiated the rolling submission of mRNA-1273 data in consideration of a potential authorization for use of the vaccine candidate in Switzerland by Swissmedic, provided it meets Swissmedic\u2019s rigorous standards of safety, effectiveness, and quality standards. This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available. This process can reduce time to authorization while maintaining usual high standards of safety, efficacy, and quality.\n<\/p>\n

\n\u201cWe appreciate the collaboration we have had to date with Swissmedic to address this ongoing public health emergency,\u201d said St\u00e9phane Bancel, Chief Executive Officer of Moderna. \u201cWe are pleased with the encouraging Phase 1 interim analysis of mRNA-1273 in the older adult population, which we recently published together with the NIH. We look forward to our expected first review of our interim efficacy data from our Phase 3 data.\u201d\n<\/p>\n

\nThe Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. mRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at the 100 \u00b5g dose level in the U.S. On October 22, Moderna completed enrollment<\/a> of the Phase 3 COVE study and on November 11, Moderna completed case accrual<\/a> for the first interim analysis of the Phase 3 COVE study. For more information about the COVE study, click here<\/a>.\n<\/p>\n

About Moderna<\/b><\/p>\n

\nModerna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body\u2019s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company\u2019s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.\n<\/p>\n

\nHeadquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science<\/i> for the past six years. To learn more, visit www.modernatx.com<\/a>.\n<\/p>\n

Forward-Looking Statements <\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company\u2019s plans to seek authorization for the use of mRNA-1273 in Switzerland; the potential for mRNA-1273 to induce rapid and strong immune responses against SARS-CoV-2; and the review of interim results from the Phase 3 trial of mRNA-1273. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no commercial product using mRNA technology has been approved and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines; despite having ongoing interactions with the FDA, Swissmedic or other regulatory agencies, the FDA, Swissmedic or such other regulatory agencies may not agree with the Company\u2019s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; the fact that the rapid response technology in use by Moderna is still being developed and implemented; potential adverse impacts due to the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those risks and uncertainties described under the heading \u201cRisk Factors\u201d in Moderna\u2019s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC\u2019s website at www.sec.gov<\/a>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna\u2019s current expectations and speak only as of the date hereof.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201113005375\/en\/<\/a><\/span><\/p>\n

Moderna Contacts
\n<\/b><\/p>\n

Media:
\n
Colleen Hussey
\n
Director, Corporate Communications
\n
617-335-1374
\n
Colleen.Hussey@modernatx.com
\n<\/a><\/p>\n

Investors:
\n
Lavina Talukdar
\n
Senior Vice President & Head of Investor Relations
\n
617-209-5834
\n
Lavina.Talukdar@modernatx.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22 Rolling review accepted based on preclinical, CMC, and clinical data available to date CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Swissmedic has started a rolling review of mRNA-1273, the Company\u2019s vaccine candidate against COVID-19. This announcement follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in … <\/p>\n

Continue reading “Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380700","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSwissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22 Rolling review accepted based on preclinical, CMC, and clinical data available to date CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Swissmedic has started a rolling review of mRNA-1273, the Company\u2019s vaccine candidate against COVID-19. This announcement follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in … Continue reading "Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T12:21:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)\",\"datePublished\":\"2020-11-13T12:21:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/\"},\"wordCount\":1084,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/\",\"name\":\"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-13T12:21:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/","og_locale":"en_US","og_type":"article","og_title":"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk","og_description":"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22 Rolling review accepted based on preclinical, CMC, and clinical data available to date CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Swissmedic has started a rolling review of mRNA-1273, the Company\u2019s vaccine candidate against COVID-19. This announcement follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in … Continue reading \"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T12:21:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)","datePublished":"2020-11-13T12:21:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/"},"wordCount":1084,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/","name":"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-13T12:21:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201113005375r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Swissmedic Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380700"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380700\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}